Cytogenetic profile of chronic myeloid leukaemia patients resistant to imatinib at tertiary level in Indonesia

Chronic Myeloid Leukemia (CML) is primarily driven by the Philadelphia chromosome, producing the BCR::ABL1 fusion protein. Although imatinib significantly improved CML outcomes, resistance remains a key challenge. Resistance often leads to cytogenetic abnormalities (ACAs), indicating poor disease prognosis. This is the first study that investigates genetic profiles in imatinib-resistant Indonesian CML patients. The study included adult chronic-phase CML patients who met the criteria of treatment failure under the treatment of imatinib. Peripheral blood samples and bone marrow samples were collected and then processed for cytogenetic examination following the International System of Human Cytogenetic Nomenclature (ISCN) guidelines. BCR::ABL1 transcript levels were measured using Quantitative Real-Time PCR. Out of 27 CML patients, the mean age was 39.15 years, with a male-to-female ratio of 1:1.5. The mean BCR::ABL1 international scale (IS) value was 37.20 ± 4.56, and patients on tyrosine kinase inhibitor (TKI) therapy had a median treatment duration of 80 months. Cytogenetic analysis showed Philadelphia chromosome (Ph) positivity in 11.11% of peripheral blood and 34.78% of bone marrow samples, with Ph negativity in 25.93% and 17.93%, respectively. Peripheral blood abnormalities included trisomy 8 (11.11%), additional Ph (7.41%), trisomy 19 (3.70%), and complex karyotypes (14.81%), while bone marrow abnormalities included trisomy 8 (13.04%), additional Ph (8.69%), trisomy 21 (4.35%), monosomy 7/7q- (8.70%), and complex karyotypes (43.45%). Cytogenetic anomalies such as trisomy 8, trisomy 19, and complex karyotypes may contribute to TKI resistance. Further study is needed to understand additional abnormalities observed.

• Publication year

  2025

• Venue

  Molecular Cytogenetics

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13039-025-00737-0PMID 41225551PMCID 12607101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia

  2024cited by this paper
• European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

  2023cited by this paper
• High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population

  2023cited by this paper
• Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis

  2022cited by this paper
• Transplantation in CML in the TKI era: who, when, and how?

  2022cited by this paper
• Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

  2022cited by this paper
• Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia

  2022cited by this paper
• Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

  2021cited by this paper
• Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

  2021cited by this paper
• Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.

  2021influential reference
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

  2020cited by this paper
• Cancer statistics, 2020

  2020cited by this paper
• Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

  2020cited by this paper
• Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017

  2020cited by this paper
• Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients

  2019cited by this paper
• A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation?

  2018cited by this paper
• Chronic Myeloid Leukemia: Beyond BCR-ABL1

  2018cited by this paper
• Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

  2017cited by this paper
• Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

  2017cited by this paper
• Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities

  2016cited by this paper
• Location of the BCR/ABL Fusion Genes on Both Chromosomes 9 in Ph Negative Young CML Patients: An Indian Experience

  2014cited by this paper
• [Chronic myelogenous leukemia].

  2013cited by this paper
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

  2013cited by this paper
• Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

  2011cited by this paper
• Significant Discrepancy In Peripheral Blood Compared to Bone Marrow BCR-ABL Transcript Levels In Chronic Phase Chronic Myeloid Leukemia (CML)

  2010cited by this paper
• Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia.

  2005cited by this paper

• No citing papers are available for this paper.